Azer-Cel is closest to FDA approvals . That’s what attracts the money. That’s why IMU are focussed on Cancers that can be Fast Tracked.
Build up the HYPE on Azer-Cel. Project the image of it being the best option for a CD19 targeted Allogeneic CarT.
Then when FDA approvals are in place, the reputation of Azer-Cel is established, IMU announces that Axer-Cel will be trialled with Oncarlytics which will open up the solid tumor market. We are aiming for a 50+% response rate in the previously unaddressed market with a clear unmet need.
This isn’t about CF33 not working, it’s about positioning all our platforms to gain momentum with investors!
IMU Price at posting:
3.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)